Formulary amendments September 2025 & horizon scanning October 2025
Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in September 2025:
- Monthly formulary amendments – September 2025
- Monthly horizon scanning – October 2025
Regional prescribing position; North West region: September 2025
The purpose of this bulletin is to provide the regional team with an overview of the primary care prescribing position in the North East & Yorkshire region, the progress made in the National Medicines Optimisation Opportunities and the wider focus on prescribing for the North East and Yorkshire ICBs.
The bulletin for the North West region can be found here
RDTC workplan – adrenaline nasal spray
During routine horizon scanning, RDTC have identified adrenaline 2mg nasal spray (Eurneffy) for management of severe allergic reactions as an item of interest. We’ve added it to our workplan, but we’re aware that the Resuscitation Council UK clinical guidelines are due for review. To avoid duplication of effort we are awaiting this updated guidance, and will keep this topic under active surveillance,
Evidence reviews for drug and therapeutics committees
RDTC are making a new series of publications available to stakeholders. Our D&T reviews are prepared in response to specific requests, and intended for use by drug and therapeutics groups or equivalent committees, They provide an overview of the evidence on a specific therapeutic question, and support the review of applications to use a treatment in an individual or for a cohort. They are not intended to be used as standalone publications.
For a list of the topics available, visit the D&T reviews page.
Budget impact of prescribing haloperidol 500 microgram tablets
The purpose of this bulletin is to highlight the inflated NHS price of haloperidol 500 microgram tablets and to demonstrate the potential savings of using alternative presentations to provide the same dose. It shows the current annual primary care spend on haloperidol 500 microgram tablets and potential annual opportunity within RDTC stakeholder ICBs.
The bulletin on the budget impact of prescribing haloperidol 500 microgram tablets can be accessed here
Monthly Horizon Scanning Report – September 2025
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals
This September edition can be found here
Monthly formulary amendments – August 2025
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition which covers guidance and alerts published in August 2025 can be found here
Regional Prescribing Position North East Yorkshire Region: August 2025
The purpose of this bulletin is to provide the regional team with an overview of the primary care prescribing position in the North East & Yorkshire region, the progress made in the National Medicines Optimisation Opportunities and the wider focus on prescribing for the North East and Yorkshire ICBs.
The bulletin for the North East & Yorkshire region can be found here
RDTC reports, publications, resources demo and Q&A sessions
The RDTC are offering a series of sessions for NHS colleagues to attend a relaxed demo of RDTC resources. We’ll bring a few of the RDTC team; analysts, scientists and pharmacists, you’re welcome to bring a cuppa and any questions you might have.
Sessions will be delivered by Microsoft Teams and will last around an hour, including time for you to ask questions. The available sessions are:
| Date | Time | Topics covered |
| Week commencing 18th November, date TBC | 10:30am-11:30am | Antimicrobial stewardship |
To book your place and receive an MS Teams link, please email: nuth.nyrdtc.rxsupp@nhs.net with the details of the session(s) you would like to attend.
If you are unable to attend on the dates/times available but would like to, or if you would like to request a specific demonstration session for yourself and colleagues, please email us to discuss alternative options.
Pylera for the eradication of Helicobacter Pylori infection
Pylera is a new triple fixed-dose combination capsule containing bismuth, metronidazole and tetracycline. In combination with omeprazole, it is indicated for the eradication of H. pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers. The aim of this report is to evaluate the efficacy, safety and potential place in therapy of Pylera.
The Medicines in Practice bulletin for Pylera can be accessed here